Ignite Creation Date:
2024-05-06 @ 1:13 PM
Last Modification Date:
2024-10-26 @ 1:10 PM
Study NCT ID:
NCT03964233
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2019-05-24
Brief Title:
A Study in Patients With Different Types of Advanced Cancer Solid Tumors to Test Different Doses of BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab and BI 754111 or BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-11
Start Date Type:
ACTUAL
Primary Completion Date:
2024-09-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-05-24
First Submit QC Date:
May 24 2019
Study First Post Date:
2019-05-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-01
Last Update Post Date:
2024-07-09
Last Update Post Date Type:
ACTUAL